Shares of Medidata Solutions Inc (NASDAQ:MDSO) have received an average rating of “Buy” from the fourteen ratings firms that are presently covering the company. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $60.44.
Several research firms have weighed in on MDSO. Jefferies Group LLC reiterated an “underperform” rating and set a $47.00 price objective (up previously from $46.00) on shares of Medidata Solutions in a research report on Thursday, February 16th. Zacks Investment Research upgraded Medidata Solutions from a “hold” rating to a “strong-buy” rating and set a $66.00 price objective on the stock in a research report on Wednesday, February 15th. Piper Jaffray Companies increased their price objective on Medidata Solutions from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday. SunTrust Banks, Inc. upgraded Medidata Solutions from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $60.00 to $70.00 in a research report on Friday, February 10th. Finally, Needham & Company LLC increased their price objective on Medidata Solutions from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, February 10th.
In related news, CEO Tarek Sherif sold 2,964 shares of the firm’s stock in a transaction on Tuesday, April 4th. The stock was sold at an average price of $57.08, for a total value of $169,185.12. Following the transaction, the chief executive officer now owns 815,356 shares in the company, valued at $46,540,520.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Vice Chairman Steven Isaac Hirschfeld sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $50.83, for a total value of $508,300.00. The disclosure for this sale can be found here. Insiders sold 32,964 shares of company stock worth $1,806,510 in the last 90 days. 6.70% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC boosted its position in shares of Medidata Solutions by 90.0% in the third quarter. Acrospire Investment Management LLC now owns 1,900 shares of the company’s stock worth $106,000 after buying an additional 900 shares during the last quarter. Tyers Asset Management LLC bought a new position in shares of Medidata Solutions during the fourth quarter worth approximately $131,000. Flinton Capital Management LLC bought a new position in shares of Medidata Solutions during the fourth quarter worth approximately $159,000. Pacer Advisors Inc. bought a new position in shares of Medidata Solutions during the third quarter worth approximately $191,000. Finally, Princeton Alpha Management LP bought a new position in shares of Medidata Solutions during the third quarter worth approximately $226,000. Institutional investors own 99.63% of the company’s stock.
Shares of Medidata Solutions (NASDAQ:MDSO) traded down 1.29% on Monday, reaching $60.30. 276,602 shares of the company traded hands. The firm’s 50 day moving average is $57.53 and its 200 day moving average is $53.55. Medidata Solutions has a one year low of $39.45 and a one year high of $64.52. The company has a market capitalization of $3.37 billion, a P/E ratio of 118.24 and a beta of 1.61.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, February 9th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.07. The firm had revenue of $124.50 million for the quarter, compared to analysts’ expectations of $124.15 million. Medidata Solutions had a return on equity of 10.82% and a net margin of 6.25%. The company’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.27 EPS. Analysts expect that Medidata Solutions will post $1.25 earnings per share for the current fiscal year.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/medidata-solutions-inc-mdso-receives-59-78-consensus-price-target-from-brokerages/1739677.html
Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.